ARCHIVES

Major Changes Being Considered By NCI For FCRA

This article is from The Cancer Letter archive.

Vol. 04 No. 15 | April 14, 1978

Download PDF Visit The Full Archive

Related Articles

Guest Opinion: Long Island Study’s Value Now Rests In Its Repository

November 2, 2002

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

May 25, 2001

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

December 5, 2014

Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication

November 25, 2011

Tumors Harder To Detect In Women In Their Forties

August 27, 2010

Prostatic Cancer Workshop Reports On Etiology, Diagnosis, Treatment

September 10, 1976